The broader impacts/commercial potential of this Small Business Technology Transfer Research (STTR) Phase II project are the potential to advance RNA therapeutic solutions across a wide range of diseases. Safe and effective RNA delivery remains a critical challenge and the primary hurdle to clinical translation of RNA therapeutics. This project’s technology is intended to help RNA therapeutics clear this hurdle, facilitating the development of safe and effective targeted RNA therapeutics for diseases plaguing human health. Vascular disease interventions have limited long-term success, and there is a critical need for effective therapeutics; this project’s work for the treatment of intimal hyperplasia represents an important step toward the ultimate goal of improving the treatment of diseases currently lacking effective therapies. This project’s innovation will also contribute to the American economy by providing a combined product and CRO business model that will enhance the RNA therapeutic market, providing flexibility and a wide range of future applications for treatment of diseases across a wide range of potential partners. This project’s innovation will also promote the creation of American jobs in science sales and manufacturing. This Small Business Technology Transfer Research (STTR) Phase II project seeks to further develop a platform technology for targeted RNA therapeutic delivery. The widespread use of RNA therapeutics is challenged by the absence of safe, targe